Therapy of acute and fulminant hepatitis B.

Published

Journal Article

Although new hepatitis B virus (HBV) infections are decreasing due to improving vaccination coverage, patients without vaccination coverage can still suffer from manifestation of acute hepatitis B with jaundice and (although rarely) liver failure. No treatment is indicated for mild acute hepatitis B; however, antiviral therapy should be initiated for patients showing signs of significant liver impairment as exemplified by deterioration of prothrombin time to an equivalent of 1.5 or 50% of the 'Quick test'. For fulminant hepatitis, there is no complete agreement on whether antiviral treatment would alter the course, but it should still be started, as it would reduce the risk of reinfection in case there is a need for liver transplantation. Patients in danger of progression towards acute liver failure should be referred to transplant centers as early as possible.

Full Text

Duke Authors

Cited Authors

  • Tillmann, HL; Patel, K

Published Date

  • January 2014

Published In

Volume / Issue

  • 57 / 3-4

Start / End Page

  • 181 - 188

PubMed ID

  • 25034486

Pubmed Central ID

  • 25034486

Electronic International Standard Serial Number (EISSN)

  • 1423-0100

International Standard Serial Number (ISSN)

  • 0300-5526

Digital Object Identifier (DOI)

  • 10.1159/000360939

Language

  • eng